Neurocrine Biosciences, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-55.4% vs price
Base Case (Median)
-51.7% vs price
Bull Case (75th pct.)
5.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $43.38 | -71.9% | High (40%) |
| PE Comparable | $151.77 | -1.8% | Medium (25%) |
| Growth Trajectory DCF | $347.95 | 125.2% | Medium (20%) |
| Graham Number | $70.83 | -54.2% | Medium (40%) |
| EV/EBITDA | $66.99 | -56.6% | Medium (20%) |
| EV/FCF | $174.95 | 13.2% | Medium (20%) |
| Earnings Power Value | $74.55 | -51.7% | Medium (50%) |
Based on 7 out of 8 methods, NBIX appears fairly valued at the current price of $154.49. The base case fair value of $74.55 implies 51.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.